Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026)

Jazz Pharmaceuticals' Long-Term Deferred Tax history runs 15 years deep, the most recent figure standing at $907.0 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 57.71% year-over-year to $907.0 million; the TTM figure through Mar 2026 stood at $907.0 million (up 57.71% YoY), while the FY2025 annual figure was $869.1 million, up 55.13% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $907.0 million, up from $869.1 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $907.0 million in Q1 2026, with the low at $314.7 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $507.7 million (2024), against an average of $535.0 million.
• The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax grew 0.1% in 2022, then soared 57.71% in 2026.
• Jazz Pharmaceuticals' Long-Term Deferred Tax stood at $376.2 million in 2022, then advanced by 27.0% to $477.8 million in 2023, then increased by 17.25% to $560.2 million in 2024, then jumped by 55.13% to $869.1 million in 2025, then rose by 4.36% to $907.0 million in 2026.
• Business Quant data shows JAZZ's Long-Term Deferred Tax at $907.0 million in Q1 2026, $869.1 million in Q4 2025, and $846.2 million in Q3 2025.